Cerviron vaginal ovules contain 7 active components that confer their beneficial therapeutic properties in multiple disorders or the female genital tract.
These properties are due to the cumulative or antagonistic effects of the components, and the low concentrations in which they are found, avoids any unwanted local effects and stimulates the immune system, restoring the initial colpoecosystem (the vaginal ecosystem, which represents a complex system, which integrates into a dynamic functional unit a biotic communion, biocenosis, consisting of all the microorganisms in the vagina, which are in interaction), without affecting the Dderlein bacilli, from the vagina, which creates conditions conducive to their development.
All of these active components are incorporated in an inert base of suppositories, semi-synthetic glycerides, which ensure a homogeneous dispersion. Due to this composition, the Cerviron product
diminishes or removes the inflammatory phenomena in the vagina and cervix, has antiseptic effects on the pathogenic intravaginal flora, but it favors the restoration of the normal microflora, diminishes or cures the erosions of the cervix, completely or partially restores the mucus trophies removes pain, burning sensations and itching in the female genital tract, accompanied by pathological hypersecretion and local and general discomfort.
Acute and chronic vulvovaginitis; cervical erosions of various etiologies, simple or infected; leucorrhea; vulvar itching; pre and postoperative treatment in gynecological surgery.
Administration of Cerviron
Intravaginal, 1 ovule in the evening, after vaginal washing, preferably starting with the first day after the end of menstrual flow, for 10-15 days per month. The improvement occurs at the first month of treatment. The treatment is repeated several months, until healing or for the consolidation and maintenance of the favorable effects obtained.
The existing informative data do not signal contraindications.
Rarely local irritation, mild, transient.
There are no reviews yet.